52-week high: $11.48
Current price: $8.07
Year-to-date performance relative to the Nasdaq Biotechnology Index: Down 14% An obesity drug? That's so 2010. Vivus might convince FDA to approve Qnexa some day but only after the company completes a 10,000-patient cardiovascular safety study. Check back in five years or so.